Karïn Gogat-Marchant

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

H. Dombret, S. Chevret, C. Preudhomme, 2018, Haematologica.